RxDoctor Payments Data

Bindu Thomas, MD

Internal Medicine · Safety Harbor, FLNPI 1447202346

Payments from drug & device makers

$2,084in general payments, 2019–2025

Across 110 payments — averaging $18.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$427
  • Pfizer$320
  • Amgen$233
  • Exact Sciences$157
  • Lilly USA, LLC$149
  • AstraZeneca$145
  • plus $652 from 12 others

What the payments were for

  • Food & beverage$2,084100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,084 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$120,241
Medicare patients
336
Services billed
1,074

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide78$72,904
JardianceEmpagliflozin43$47,623
EliquisApixaban41$44,789
XareltoRivaroxaban24$26,236
MounjaroTirzepatide17$19,541
JanuviaSitagliptin Phosphate22$17,898
FarxigaDapagliflozin Propanediol11$13,105
SynthroidLevothyroxine Sodium59$5,982
Atorvastatin Calcium639$5,627
Levothyroxine Sodium462$5,182
SymbicortBudesonide/Formoterol Fumarate14$4,075
Losartan Potassium406$3,750
Amlodipine Besylate529$3,508
Lansoprazole12$3,168
Pravastatin Sodium211$3,062

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$427$72,90478 claims
Boehringer IngelheimJardiance$46$47,62343 claims
PfizerEliquis, Paxlovid$320$46,21860 claims
Johnson & JohnsonXarelto$46$26,23624 claims
Lilly USA, LLCMounjaro$149$19,54117 claims
MerckJanuvia$32$17,89822 claims
AstraZenecaFarxiga, Symbicort$145$17,17925 claims
AbbVieSynthroid$108$5,98259 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$66$5,182462 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Safety Harbor

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →